To the editor Warfarin is a commonly used anticoagulant with a narrow therapeutic range and risk of hemorrhagic complications.[1] After CYP2C9 and VKORC1, CYP4F2 was confirmed as the third principle genetic determinant of warfarin dose variability.[2,3] CYP4F2 functions as a vitamin K1 (VK1) oxidase, a counterpart to vitamin K oxidize reductase (encoded by VKORC1) in limiting excessive accumulation of VK1 in vitamin K cycle.[4]
展开▼
机译：Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
机译：Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis
